Investments, Funding & Disinvestment

The investment, which is approaching KSh 1 billion (US$7.7 million), is expected to reduce the distance patients travel to access specialist ophthalmic services.

Axogen expects to complete the transaction in the fourth quarter of 2026, adding BioCircuit’s NerveTape to its portfolio.

The facility will add to ABEC’s existing manufacturing operations in Bethlehem, Pennsylvania, and Springfield, Missouri, as well as its facilities in Fermoy and Kells, Ireland.

Moscow has used computer vision in healthcare for more than six years, with more than 70 AI services supporting doctors in analysing medical images, including CT scans, MRI examinations, and X-rays.

The expanded facility will allow Siemens Healthineers to increase production of its PET detector technology and respond to growing demand from healthcare providers.

It will house about 325 employees, including 260 laboratory scientists, and provide adaptable laboratories, collaborative workspaces and shared technology platforms.

The facility is expected to produce 10 million nets annually at full capacity and create more than 600 jobs.

Solstice Oncology plans to begin enrolment in a Phase II clinical trial of porustobart in combination with pembrolizumab in the fourth quarter of 2026.

Encoded plans to use the proceeds primarily to fund a pivotal trial of ETX101 in infants and young children with SCN1A positive Dravet syndrome.

The acquisition brings MLM’s laboratory infrastructure and scientific expertise into Labcorp’s global network, creating a broader platform to support clinical trials across multiple regions.